Document Detail

Pharmacokinetics of butyric acid derivative with xylitol.
MedLine Citation:
PMID:  1820907     Owner:  NLM     Status:  MEDLINE    
The short chain fatty acids, especially butyric acid salts have interesting biological properties. In some cases, transformed cells can recover a normal phenotype and in animal, butyrate salts increase antitumor resistance. Butyrate may be considered as possibly useful for antitumor therapy. But these products exhibit two essential disadvantages which restrict their clinical use in man: high concentrations required to achieve therapeutic effects and rapid excretion with short half life. In order to optimize the clinical use of butyrate, we studied a n-butyric acid ester obtained with xylitol selected for its physiological and metabolic inertia. Structure determination of tributyryl xylitol was carried out by mass and NMR spectrometry (MW = 344). The low toxicity and the antitumor effects of this ester, especially in association with Corynebacterium parvum and interferon, confirm its therapeutic interest. The slow excretion of this prodrug should make butyrate clinical use easier by preventing extensive systemic metabolism and metabolic side-effects due to cations of butyrate salts.
G Desmet; M Brazier; J Cerutti; C Chany; M L Arnould-Guerin
Related Documents :
4577487 - Production of a sporulation pigment by streptomyces venezuelae.
3079997 - Further studies on the inhibition of pepsin by bile salts.
1808607 - Solubilization and wetting effects of bile salts on the dissolution of steroids.
2153027 - An investigation of the dissociation and denaturation of legumin by salts using laser l...
16326817 - In vitro and in vivo evaluation of the metabolism and bioavailability of ester prodrugs...
14984087 - Marmenol: a 7-geranyloxycoumarin from the leaves of aegle marmelos corr.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of drug metabolism and pharmacokinetics     Volume:  Spec No 3     ISSN:  0378-7966     ISO Abbreviation:  Eur J Drug Metab Pharmacokinet     Publication Date:  1991  
Date Detail:
Created Date:  1992-08-10     Completed Date:  1992-08-10     Revised Date:  2011-02-02    
Medline Journal Info:
Nlm Unique ID:  7608491     Medline TA:  Eur J Drug Metab Pharmacokinet     Country:  FRANCE    
Other Details:
Languages:  eng     Pagination:  348-51     Citation Subset:  IM    
Laboratoire d'Hormonologie, C.H.U., Amiens, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / pharmacology
Butyrates / chemical synthesis,  pharmacokinetics*,  pharmacology
Lethal Dose 50
Magnetic Resonance Spectroscopy
Mass Spectrometry
Prodrugs / chemical synthesis,  pharmacokinetics*
Sarcoma, Experimental / drug therapy
Xylitol / analogs & derivatives,  pharmacokinetics*,  pharmacology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Butyrates; 0/Prodrugs; 87-99-0/Xylitol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacoki...
Next Document:  Homeostatic equilibrium of L-carnitine family before and after i.v. administration of propionyl-L-ca...